<DOC>
	<DOCNO>NCT00527475</DOCNO>
	<brief_summary>Single agent anti-VEGF therapy ranibizumab show great promise set standard visual outcome treat wet macular degeneration . However , need administer frequently intraocular injection attendant risk endophthalmitis , lens damage , retinal detachment , vitreous hemorrhage . The purpose trial see use photodynamic therapy combination ranibizumab decrease number treatment ranibizumab .</brief_summary>
	<brief_title>Ranibizumab Reduced Fluence PDT AMD</brief_title>
	<detailed_description>A randomize , prospective , multicenter trial compare two group patient subfoveal choroidal neovascularization secondary AMD . One group receive 0.5 mg. ranibizumab intraocularly initially . This repeat monthly 3 month total need period one year . The group receive Reduced Fluence-PDT ( 25 Joules ) follow 0.5 mg. ranibizumab intraocularly day . The second group receive combination ranibizumab RF-PDT need period one year . Re-treatment determine individual investigator base visual acuity , retinal thickness measure optical coherence tomography ( OCT ) , fluorescein angiography . Visual acuity OCT measurement perform masked examiner .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>1 . Willingness sign inform consent . 2 . Age great 50 . 3 . Evidence macular degeneration form drusen either eye . 4 . Visual acuity 20/25 20/800 . 5 . Subfoveal choroidal neovascularization . Both occult classic subtypes allow . If lesion purely occult one following : 1 . Recent loss vision ( 5 letter ETDRS double visual angle snellen ) 2 . Documented enlargement lesion FA 3 . Increase 50 micron central subfield OCT 4 . New blood 6 . Total active lesion must less 12 disc area size . 1 . Myopia , ocular histoplasmosis , retinal pathology could affect vision 2 . Previous treatment enrol eye CNV 3 . Intraocular surgery within 6 week enrollment 4 . Geographic atrophy , subretinal fibrosis , pigment epithelial tear involve fovea eligible eye 5 . Known hypersensitivity verteporfin 6 . Medical condition would preclude regular followup one year . 7 . Previous vitrectomy 8 . Media opacities limit visual acuity , retinal examination , retinal imaging . 9 . A lesion &gt; 50 % lesion pigment epithelial detachment .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Anti-VEGF therapy</keyword>
	<keyword>photodynamic therapy</keyword>
	<keyword>neovascularization</keyword>
</DOC>